Akebia Therapeutics

173 articles with Akebia Therapeutics

• Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

  5/9/2019

  Akebia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019. The company also announced full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer.

• Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

  5/2/2019

  Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease

• Akebia Therapeutics to Report First Quarter 2019 Financial Results

  4/30/2019

  Akebia Therapeutics, Inc. announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets.

• Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement

  4/9/2019

  Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval

• Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement - April 9, 2019

  4/9/2019

  Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval

• Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference

  4/5/2019

  Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2019

  4/2/2019

  Akebia Therapeutics, Inc. granted 16 newly-hired employees options to purchase an aggregate of 225,000 shares of Akebia’s common stock on March 29, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• 

  Genetown, a Hotbed of Innovation and Drug Development

  4/2/2019

  The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.

• Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

  3/18/2019

  First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with anemia due to chronic kidney disease

• Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease

  3/12/2019

  Akebia Therapeutics, Inc. announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), in Japanese subjects with anemia due to chronic kidney disease (CKD).

• 

  FDA Green-Lights Two Therapies, While Late-Stage Successes Set Stage for Potential Approvals

  3/12/2019

  The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval.

• Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast

  3/6/2019

  Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, March 18, 2019.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 4, 2019

  3/4/2019

  Akebia Therapeutics, Inc. granted 11 newly-hired employees options to purchase an aggregate of 32,800 shares of Akebia’s common stock on February 28, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on January 31, 2019

  2/4/2019

  Akebia Therapeutics, Inc. granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebia’s common stock on January 31, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Akebia Therapeutics, Inc. today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30 a.m. Pacific Time at the Westin St. Francis in San Francisco.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on December 31, 2018

  1/2/2019

  Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebia’s common stock on December 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

  12/13/2018

  Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger.

• Akebia Therapeutics Shareholders Approve Merger with Keryx

  12/11/2018

  Akebia Therapeutics, Inc. today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) at a special meeting of Akebia shareholders held earlier today. More than 95% of the shares voted at the special meeting voted in favor of the share issuance proposal.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on November 30, 2018

  12/3/2018

  Akebia Therapeutics, Inc. granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Akebia’s common stock on November 30, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

• Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

  11/30/2018

  Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia shareholders vote “FOR” the shareholder proposals relating to the Company’s proposed merger with Keryx Biopharmaceuticals (Nasdaq:KERX).